Notably, emerging research has revealed that a subset of AML patients, particularly those with t(8;21)-positive AML-M2b, may exhibit aberrant expression of CD19, and early case reports indicated that CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy could be effective (2–4). This evidence concerns the gene CD19 and acute myeloid leukemia.